Warning
Wells Pharma of Houston LLC Recalls fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0508-2026Drug / Pharmaceutical
Wells Pharma of Houston LLC Recalls fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride
Wells Pharma of Houston LLC · Class II — Moderate Risk
Product Description
fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.
Reason for Recall
cGMP deviations.
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
U.S. Nationwide.
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
The FDA classified this recall as Class II, indicating the pharmaceutical product may cause temporary health problems or poses a slight threat of a serious nature. Wells Pharma of Houston LLC initiated the recall on April 1, 2026 affecting 50 syringes. cGMP deviations. The product was distributed in U.S. Nationwide. Consumers should check their purchases and discontinue use of any affected product. Contact Wells Pharma of Houston LLC for further instructions.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medication Defects.